someone post the address of corx for me, thanks..
This is learning experience for me, will ride by and report to thread, not trying to hype another stock here, but what really strikes me is the huge differences between HEB and CORX, the contrasts are telling sign for me....
1 heb 326 patents corx 5
2 heb phase 3, orphan status as well as cost recovery status, corx conflicting info raging about as to status of research, p1 or p2, rats only or human testing as well, nbc piece coupled with lack of clarity from ir adding to this confusion. remember confusion creates doubt, doubt creates fear, fear creates panic, panic creates a sell-off, corx's failure to disseminate accurate and timely shareholder updates has hurt this stock value.
3 heb only potential cure for cfs, corx maybe one of many potential cures for altzheimers
4 heb almost daily press releases as well as constantly updated website, corx ir woman who tells nothing to investors for over 2 years
5 heb manufacturing(company in south africa) in place, corx doesnt address this issue anywhere
6 heb aligned with quality names like olsten, corx going it alone
7 heb has no rivals, corx has neot hot on its heels
a drug needs to have desperate potential users exerting massive pressure on fda to get the approval process moving at normal speed,
who is going to fight for altzheimers cure, assisted living facilities whose future depends on no cure for altz, the people with altzheimers, the children whose life is burdened with elder care,
the only one who cares are people selling long term care policies which have altzheimers as a benefit trigger, not life and death no pressure on fda to speed up corx's approval status, this is what's killing corx, imo.
people are spending every dime they have in the world to get ampligen
in cost recovery tests, without ampligen they have no hope,
86% have renewed their enrollment after first 24 weeks, telling sign to me.
cav
|
